| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司成立于2009年，其前身为上海谊众生物技术有限公司，位于上海市奉贤区仁齐路79号。公司致力于抗肿瘤药物新剂型及相关产品的开发，是一家集研发、生产、销售为一体的高科技制药企业。 上海谊众现有一支药物制剂、药物分析、高分子材料合成等专业背景的高素质研发团队，拥有符合GMP标准的先进生产设备和检验仪器。公司是国内改良型新药的创新先锋企业，拥有纳米技术和药用高分子辅料制备的核心关键技术，在纳米给药系统具有独特的创新性，可针对临床应用的经典药物采用不同分子量药用辅料通过该技术进行剂型改良，大幅提升其安全性和有效性，赋予其新的价值和生命力。 目前，已成功研发出抗肿瘤大品种化疗药紫杉醇的新剂型：注射用紫杉醇聚合物胶束，并被列入2016年度国家“重大新药创制”科技重大专项“十三五”第一批项目。已经完成大规模确证性III期临床研究，临床试验结果表明：无论疗效还是安全性，公司的注射用紫杉醇聚合物胶束均大幅优于同类产品，在晚期非小细胞肺癌（NSCLC）化疗发展历程中具有里程碑意义。 上海谊众以“不断创新”为企业唯一发展战略，以“第一、唯一、安全、前进”为公司核心价值理念。做济世良药，竭力挽救患者生命，为患者创造奇迹，为社会创造价值。 | ||||||||||||||||||||||||
| Main Business | 主要从事抗肿瘤药物改良型新药的研发和产业化 | ||||||||||||||||||||||||
| Legal Representative | 周劲松 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 方舟 | ||||||||||||||||||||||||
| Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
| Auditors | 容诚会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-37190005 | ||||||||||||||||||||||||
| Fax No | 021-37190005-8037 | ||||||||||||||||||||||||
| Website | www.yizhongpharma.com | ||||||||||||||||||||||||
| info@yizhongpharma.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 09/09/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.020 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.310 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 9.255 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 8.539B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |